Commercialization Payment definition

Commercialization Payment has the meaning ascribed to it in Section 5.3.
Sample 1Sample 2
Commercialization Payment has the meaning given to it in the definition of “Post-Closing Merger Consideration” in Section 1.1.
Sample 1Sample 2
Commercialization Payment is as defined in Section 5.2.
Sample 1

Examples of Commercialization Payment in a sentence

  • Pfizer shall calculate all Commercialization Payments payable to Auxilium pursuant to Section 8.3 with respect to Net Sales at the end of each Pfizer Quarter, which amounts shall be converted to Dollars at such time in accordance with Section 8.7. Pfizer shall pay to Auxilium the Commercialization Payment due for Net Sales during a given Pfizer Quarter within forty-five (45) days after the end of such Pfizer Quarter.

  • In the event that Pfizer makes payments pursuant to Section 8.4.2, Pfizer shall be entitled to offset the amount by which such payment exceeds the Commercialization Payment that would have otherwise been due to Auxilium against future Commercialization Payments.

  • Effective from and after the Closing Date, the Purchaser hereby agrees that it shall carry a product liability insurance policy (the “Insurance Policy”) covering the Project, the Amadeus Device and each other Product in an amount of not less than U.S.$2,000,000 until the tenth anniversary of the Commercialization Payment Date.

  • The consideration for the Purchased Assets consists of (a) the payment at the Closing of $3,000,000 (the “Closing Payment”), (b) the Commercialization Payment to be paid in accordance with Section 2.6, (c) the Initial Sales Percentage Amounts and Sales Percentage Amounts, as applicable, to be paid in accordance with Section 2.7 (the amounts set forth in clauses (a), (b) and (c), the “Purchase Price”), and (d) the assumption of the Assumed Liabilities.

  • Any Commercialization Payment will be paid in equal monthly installments of $52,083.33 over the 24-month-period beginning immediately after the commercialization of each such product.

  • Oncorus shall pay an Annual Commercialization Payment of $[***]m USD per year, for each Indication in which each Product in combination with each Checkpoint Blockade Agent is approved, payable on the first anniversary after Regulatory Approval and First Commercial Sale of such Product in the first Major Market Country.

  • Each Commercialization Payment is payable one time only, regardless of the number of times the condition is satisfied.

Related to Commercialization Payment

  • Commercialization Costs means the out-of-pocket costs and expenses incurred by Adapt or its Affiliates directly attributable to, or reasonably allocable to, the Commercialization of a Product. Commercialization Costs for a Product shall include, preparation of promotional, advertising, communication, medical, and educational materials relating to the Product and other Product literature and selling materials, activities directed to marketing of the Product, including purchase of market data, development and conduct of market research, advertising, public relations, public affairs and other communications with Third Parties regarding the Product; development and conduct of sales force training (including materials, programs and travel to and attendance at training programs) for medical representatives responsible for promoting the Product; and development and maintenance of sales bulletins, call reporting and other monitoring/tracking, sales force targeting, validation and alignment programs and documentation.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Development Activities means those activities which are normally undertaken for the development, construction, repair, renovation, rehabilitation or conversion of buildings for residential purposes, including the acquisition of property;

  • Sales Milestone Payment shall have the meaning set forth in Section 8.4.

  • Development Plan has the meaning set forth in Section 3.2.

  • Development Activity means any activity defined as Development which will necessitate a Floodplain Development Permit. This includes buildings, structures, and non-structural items, including (but not limited to) fill, bulkheads, piers, pools, docks, landings, ramps, and erosion control/stabilization measures.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Development Milestone is defined in Section 5.3.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Milestone Payment has the meaning set forth in Section 4.2.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Development Milestone Event has the meaning set forth in Section 7.2.1.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Development Program means the implementation of the development plan.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Clinical Studies means human clinical trials for a Licensed Product and any other tests and studies for a Licensed Product in human subjects.